EUVIMEDEUVIMED entdecken
Open Access

A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling

Xiao Wang, Jessica B Long, John Rothen, Sida Huang, Pamela R Soulos, Sarah B Goldberg, Timothy J Robinson, Shuangge Ma, Ronac Mamtani, Carolyn J Presley, Shi-Yi Wang, Natalia Kunst und 2 weitere

Journal of the National Comprehensive Cancer Network · 2026

DOI: 10.6004/jnccn.2025.7131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026. Verfasst von Xiao Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: 1Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT. Hauptthemen laut MEDLINE: Molecular Targeted Therapy, Genomics, Carcinoma, Non-Small-Cell Lung, Precision Medicine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Broad genomic profiling (BGP) is increasingly used to determine eligibility of molecularly targeted cancer therapies. Understanding the population-level impact of BGP on treatment selection requires a clinically oriented framework guiding interpretation of the guideline-directed actionability of BGP results.

Methods

We developed the Yale Molecular Alteration Taxonomy for Real-World Individualized Treatments (Y-MATRIX) to classify BGP results in relation to contemporaneous FDA approvals and NCCN Guidelines. We then applied our schema to patients with advanced non–small cell lung cancer (aNSCLC) and assessed temporal changes in the distribution of alteration categories using a large, nationwide database of patients with aNSCLC diagnosed from 2017 to 2023.

Results

Y-MATRIX classifies molecular testing results as categories A (first-line option), B (later-line option), C (off-label, guideline-concordant option), D (off-label, guideline-discordant option), E (no actionable alterations), or X (no alterations detected). In a sample of 8,717 patients with aNSCLC (median age, 69 years; 49.2% female), the proportion of patients in category A/B increased from 15.8% in 2017 to 33.6% in 2023, driven predominantly by an increase in later-line therapies (category B, 0% to 15.2%). Patients in category C/D increased from 21.2% to 39.3%, whereas patients in category E/X decreased markedly from 63.1% to 27.1%. Nonsmoking status, younger age, and nonsquamous histology were associated with having category A alterations.

Conclusions

Y-MATRIX provided a comprehensive taxonomy of BGP results by clinical actionability and demonstrates the increasing actionability of BGP results as the aNSCLC treatment landscape evolved over time. There was an increase in patients with category C and D findings, representing a diverse set of clinical circumstances of unclear actionability with opportunities for both innovative and potentially inappropriate targeted therapy use. The Y-MATRIX schema can be applied to facilitate research on all cancers, including the study of alterations across strata of targetable potential and the clinical utility of molecular profiling in precision oncology over time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Targeted TherapyGenomicsCarcinoma, Non-Small-Cell LungPrecision MedicineLung NeoplasmsBiomarkers, TumorHumansFemaleAgedMaleMiddle AgedGene Expression Profiling

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • 1Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
  • 2Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale Cancer Center, New Haven, CT.
  • 3Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven CT.
  • 4Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT.
  • 5Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT.
  • 6Department of Biostatistics, Yale School of Public Health, New Haven, CT.

Förderung

  • NCI NIH HHS

Zitieren

APA

Wang, X., Long, J. B., Rothen, J., Huang, S., Soulos, P. R., Goldberg, S. B., Robinson, T. J., Ma, S., Mamtani, R., Presley, C. J., Wang, S. Y., Kunst, N., Gross, C. P., & Dinan, M. A. (2026). A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2025.7131

Vancouver

Wang X, Long JB, Rothen J, Huang S, Soulos PR, Goldberg SB, et al. A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling. Journal of the National Comprehensive Cancer Network. 2026. doi:10.6004/jnccn.2025.7131

BibTeX
@article{Wang2026,
  author = {Wang, Xiao and Long, Jessica B and Rothen, John and Huang, Sida and Soulos, Pamela R and Goldberg, Sarah B and Robinson, Timothy J and Ma, Shuangge and Mamtani, Ronac and Presley, Carolyn J and Wang, Shi-Yi and Kunst, Natalia and Gross, Cary P and Dinan, Michaela A},
  title = {A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2026},
  doi = {10.6004/jnccn.2025.7131}
}
Kostenlos starten →